Cargando…

CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer as the absence of cell surface receptors renders it more difficult to be therapeutically targeted. Chemokine receptor 2 (CXCR2) has been suggested not only to promote therapy resistance and suppress immunotherapy but...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghallab, Alaa M., Eissa, Reda A., El Tayebi, Hend M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065340/ https://www.ncbi.nlm.nih.gov/pubmed/35517812 http://dx.doi.org/10.3389/fphar.2022.862125

Ejemplares similares

A cutting-edge immunomodulatory interlinkage between HOTAIR and MALAT1 in tumor-associated macrophages in breast cancer: A personalized immunotherapeutic approach
por: Amer, Hoda T., et al.
Publicado: (2022)

Thymoquinone, a Novel Multi-Strike Inhibitor of Pro-Tumorigenic Breast Cancer (BC) Markers: CALR, NLRP3 Pathway and sPD-L1 in PBMCs of HR+ and TNBC Patients
por: Elgohary, Sawsan, et al.
Publicado: (2023)

Immunoadjuvant Nanoparticles as Trojan Horses for Enhanced Photo-Immunotherapy in the Treatment of Triple-Negative Breast Cancer
por: Wu, Jinxian, et al.
Publicado: (2022)

Lupeol synergizes with 5-fluorouracil to combat c-MET/EphA2 mediated chemoresistance in triple negative breast cancer
por: Mitra, Debarpan, et al.
Publicado: (2023)

Identification of Antibody and Small Molecule Antagonists of Ferroportin-Hepcidin Interaction
por: Ross, Sandra L., et al.
Publicado: (2017)

Editorial: Advances in antimicrobial therapy and combating resistance
por: Ghazi, Islam M., et al.
Publicado: (2023)

Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data
por: Huynh, Christine, et al.
Publicado: (2022)

The fate of chemoresistance in triple negative breast cancer (TNBC)
por: O’Reilly, Elma A., et al.
Publicado: (2015)

Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers
por: Abd El-Aziz, Yomna S., et al.
Publicado: (2021)

Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy
por: Komorowski, Marcin P, et al.
Publicado: (2016)

The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer
por: Shi, Yi, et al.
Publicado: (2020)

Novel strategies to target chemoresistant triple-negative breast cancer
por: Venkatesh, Jaganathan, et al.
Publicado: (2020)

DSTYK Enhances Chemoresistance in Triple-Negative Breast Cancer Cells
por: Ogbu, Stella C., et al.
Publicado: (2021)

Bioactive nanotherapeutic trends to combat triple negative breast cancer
por: Chowdhury, Pallabita, et al.
Publicado: (2021)

Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
por: Ghallab, Ahmed
Publicado: (2020)

Editorial: Targeting triple negative breast cancer by natural compounds
por: Kumar, Shashank, et al.
Publicado: (2023)

Adenosine Receptor Antagonists to Combat Cancer and to Boost Anti-Cancer Chemotherapy and Immunotherapy
por: Franco, Rafael, et al.
Publicado: (2021)

Targeting Nrf2 Signaling to Combat Chemoresistance
por: No, Jae Hong, et al.
Publicado: (2014)

Novel approaches to combat chemoresistance against glioblastomas
por: Towner, Rheal A., et al.
Publicado: (2020)

Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists
por: Mishra, Rama K., et al.
Publicado: (2016)

Systematic evaluation of tumor microenvironment and construction of a machine learning model to predict prognosis and immunotherapy efficacy in triple-negative breast cancer based on data mining and sequencing validation
por: Gou, Qiheng, et al.
Publicado: (2022)

GPI-AP: Unraveling a New Class of Malignancy Mediators and Potential Immunotherapy Targets
por: Hussein, Nada H., et al.
Publicado: (2020)

In Vitro Pharmacological Profile of a New Small Molecule Bradykinin B(2) Receptor Antagonist
por: Lesage, Anne, et al.
Publicado: (2020)

Target Analysis and Mechanism of Podophyllotoxin in the Treatment of Triple-Negative Breast Cancer
por: Zhang, Wenfeng, et al.
Publicado: (2020)

Current landscape of personalized clinical treatments for triple-negative breast cancer
por: Zhang, Jun, et al.
Publicado: (2022)

The role of metabolic reprogramming in pancreatic cancer chemoresistance
por: Liu, Chang, et al.
Publicado: (2023)

Revisiting Preclinical Observations of Several Histamine H3 Receptor Antagonists/Inverse Agonists in Cognitive Impairment, Anxiety, Depression, and Sleep–Wake Cycle Disorder
por: Alhusaini, Mera, et al.
Publicado: (2022)

Targeting the chemerin/CMKLR1 axis by small molecule antagonist α-NETA mitigates endometriosis progression
por: Yu, Ming, et al.
Publicado: (2022)

Is There an Epigenetic Component Underlying the Resistance of Triple-Negative Breast Cancers to Parp Inhibitors?
por: Lovato, Amanda, et al.
Publicado: (2012)

SOX2 Promotes Cell Proliferation and Metastasis in Triple Negative Breast Cancer
por: Liu, Peng, et al.
Publicado: (2018)

Focus on Triple-Negative Breast Cancer: Potassium Channel Expression and Clinical Correlates
por: Lastraioli, Elena
Publicado: (2020)

Metabolomic Impact of Lidocaine on a Triple Negative Breast Cancer Cell Line
por: Chamaraux-Tran, Thiên-Nga, et al.
Publicado: (2022)

Palmatine Attenuates Metastatic Lung Colonization of Triple Negative Breast Cancer Cells
por: Ativui, Selase, et al.
Publicado: (2022)

Combating and overcoming drug resistance in cancer
por: Price, Douglas K.
Publicado: (2014)

Role of anthraquinones in combating insulin resistance
por: Xia, Wanru, et al.
Publicado: (2023)

Current approaches in treatment of triple-negative breast cancer
por: Wahba, Hanan Ahmed, et al.
Publicado: (2015)

Immunotherapy for the Treatment of Triple-Negative Breast Cancer
por: Tolaney, Sara M., et al.
Publicado: (2022)

Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021)

Optimization of small molecule degraders and antagonists for targeting estrogen receptor based on breast cancer: current status and future
por: Yao, Jiaqi, et al.
Publicado: (2023)

CXCR7 Antagonism Reduces Acute Lung Injury Pathogenesis
por: Pouzol, Laetitia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8ip68quapn49k6k1km5khlh9rc